NewAmsterdam Pharma (NASDAQ:NAMS) Stock Holdings Lifted by Decheng Capital LLC

Decheng Capital LLC grew its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 30.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 770,000 shares of the company's stock after purchasing an additional 180,000 shares during the quarter. NewAmsterdam Pharma makes up about 4.2% of Decheng Capital LLC's holdings, making the stock its 4th largest position. Decheng Capital LLC owned approximately 0.83% of NewAmsterdam Pharma worth $19,789,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Bain Capital Life Sciences Investors LLC boosted its stake in shares of NewAmsterdam Pharma by 2.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock worth $275,481,000 after buying an additional 245,197 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock worth $102,763,000 after buying an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after buying an additional 2,222,900 shares during the last quarter. Capital International Investors purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $53,007,000. Finally, Alliancebernstein L.P. purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $47,752,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper bought 1,135 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now directly owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. This trade represents a 0.04 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Stock Up 3.4 %

Shares of NAMS stock traded up $0.66 on Thursday, reaching $19.79. The company's stock had a trading volume of 365,366 shares, compared to its average volume of 896,200. The stock's 50 day simple moving average is $19.58 and its 200-day simple moving average is $21.21. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The company has a market capitalization of $2.17 billion, a P/E ratio of -7.61 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. Research analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Wall Street Analysts Forecast Growth

NAMS has been the topic of several research analyst reports. Scotiabank increased their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, Needham & Company LLC reissued a "buy" rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.